SuppreMol

12 articles with SuppreMol

• SuppreMol's Clinical Data In SLE For Its Lead Product SM101 Accepted For Presentation At The 2014 ACR / ARHP Annual Meeting In Boston

  9/9/2014

• SuppreMol Appoints Industry Expert Klaus Schollmeier as CEO

  4/3/2013

• SuppreMol Begins Development of Anti-IL-3 Monoclonal Antibody to Diagnose and Treat Early Stage Rheumatoid Arthritis

  7/27/2012

• SuppreMol Releases Positive Interim Phase Ib/IIa Results on SM101 in Primary Immune Thrombocytopenia (ITP) Trials

  3/15/2012

• SuppreMol Employs Protagen AG Biomarkers in SLE Study

  8/2/2011

• SuppreMol Receives U.S. Orphan Drug Designation for SM101

  4/22/2010

• SuppreMol Initiates Phase Ib/Iia Clinical Trial With Its Lead Candidate SM101

  4/14/2010

• SuppreMol Appoints Dr. Robert Phelps as Head of Business Development & Licensing

  2/8/2010

• SuppreMol Announces Start of Phase I Clinical Trial with its lead program SM101

  5/11/2009

• SuppreMol Announces Expansion of its Management Team and Board Changes

  10/21/2008

• SuppreMol Closes EUR 15.7 M Series B Financing Round

  7/14/2008

• SuppreMol Receives Orphan Drug Designation for SM101

  9/12/2007